<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>public and global health</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>public and global health | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis
Authors: Hoffmann, S. S.; Nielsen, S.; Thysen, S. M.; Duriseti, R.; Benn, C. S.
Score: 1288.5, Published: 2023-12-07 DOI: 10.1101/2023.12.07.23298573
ImportancePhase 3 randomized controlled trials (RCTs) of mRNA COVID-19 vaccines in children and adolescents showed efficacy in preventing COVID-19 infections. Vaccines may have non-specific effects; this is not assessed within the current regulatory framework.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/public-and-global-health/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="public and global health" />
<meta property="og:description" content="Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis
Authors: Hoffmann, S. S.; Nielsen, S.; Thysen, S. M.; Duriseti, R.; Benn, C. S.
Score: 1288.5, Published: 2023-12-07 DOI: 10.1101/2023.12.07.23298573
ImportancePhase 3 randomized controlled trials (RCTs) of mRNA COVID-19 vaccines in children and adolescents showed efficacy in preventing COVID-19 infections. Vaccines may have non-specific effects; this is not assessed within the current regulatory framework." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/public-and-global-health/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-12-20T10:36:27+00:00" />
<meta property="article:modified_time" content="2023-12-20T10:36:27+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="public and global health"/>
<meta name="twitter:description" content="Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis
Authors: Hoffmann, S. S.; Nielsen, S.; Thysen, S. M.; Duriseti, R.; Benn, C. S.
Score: 1288.5, Published: 2023-12-07 DOI: 10.1101/2023.12.07.23298573
ImportancePhase 3 randomized controlled trials (RCTs) of mRNA COVID-19 vaccines in children and adolescents showed efficacy in preventing COVID-19 infections. Vaccines may have non-specific effects; this is not assessed within the current regulatory framework."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "public and global health",
      "item": "https://trxiv.yorks0n.com/posts/public-and-global-health/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "public and global health",
  "name": "public and global health",
  "description": "Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis\nAuthors: Hoffmann, S. S.; Nielsen, S.; Thysen, S. M.; Duriseti, R.; Benn, C. S.\nScore: 1288.5, Published: 2023-12-07 DOI: 10.1101/2023.12.07.23298573\nImportancePhase 3 randomized controlled trials (RCTs) of mRNA COVID-19 vaccines in children and adolescents showed efficacy in preventing COVID-19 infections. Vaccines may have non-specific effects; this is not assessed within the current regulatory framework.",
  "keywords": [
    
  ],
  "articleBody": " Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis\nAuthors: Hoffmann, S. S.; Nielsen, S.; Thysen, S. M.; Duriseti, R.; Benn, C. S.\nScore: 1288.5, Published: 2023-12-07 DOI: 10.1101/2023.12.07.23298573\nImportancePhase 3 randomized controlled trials (RCTs) of mRNA COVID-19 vaccines in children and adolescents showed efficacy in preventing COVID-19 infections. Vaccines may have non-specific effects; this is not assessed within the current regulatory framework. ObjectiveConduct a systematic review and meta-analysis of the phase 3 trials to assess overall and non-specific health effects of the mRNA COVID-19 vaccines in children. Data SourcesPubMed, Embase, Clinical Trials, Web of Science, and regulatory websites were searched for RCTs of mRNA vaccines. The latest trial data was included. Study SelectionAll RCTs conducted with mRNA vaccines BNT162b2 and mRNA-1237 in children and adolescents below 18 years of age, with placebo, adjuvant, or other vaccines as controls. Two authors independently screened 1199 studies, six were included in the analysis. Data Extraction and SynthesisData on serious adverse events (SAEs) and severe adverse events (AEs) as well as organ-specific diseases was extracted following the PRISMA reporting guideline, with a focus on non-specific infectious events. Risk Ratios (RRs) comparing vaccine and placebo cohorts were calculated separately for each vaccine and combined in Mantel-Haenszel estimates. Main Outcomes and MeasuresThe primary outcome was SAEs, overall and infectious. Secondary outcomes were severe AEs and lower respiratory tract infection (LRTI) including RSV. ResultsThe analyses included 25,549 individuals (17,538 mRNA vaccine recipients and 8,011 placebo recipients). The risk of SAEs was similar for vaccine and placebo recipients. Both mRNA vaccines were associated with increased risk of severe AEs in older children. In a combined analysis, the RR was 3.77 (1.56-9.13[0.4% vs 0.1% in vaccine vs placebo recipients]) in above 5 year-olds, and 0.82 (0.53-1.29)[0.8% vs 0.9%])in younger children (p=0.003 for same effect in older and younger children). In the younger children, mRNA vaccines were associated with higher risk of LRTI (RR=3.03 (1.29-7.09)[0.6% vs 0.2%]). Conclusions and RelevancemRNA vaccines did not increase the risk of SAEs but were associated with an increased risk of severe AEs in older children, and an increased risk of LRTI in the young. Further research into the overall and non-specific health effects of mRNA vaccines is warranted. Question, Findings, and MeaningO_ST_ABSQuestionC_ST_ABSWhat is the overall health effect of mRNA COVID-19 vaccines in children? FindingsIn this systematic review and meta-analysis of phase 3 trials, mRNA vaccine vs. placebo was not associated with increased risk of serious adverse events. The mRNA vaccines were associated with higher risk of severe adverse events in children aged 5 years and older. In children younger than 5 years, mRNA vaccines were associated with a 3-fold higher risk of lower respiratory tract infections. MeaningThe results suggest that mRNA vaccines are associated with increased risk of severe adverse events and increased risk of LRTI. Given the low risk of severe COVID-19 infection in children, it is not clear that the benefits of COVID-19 vaccines in children outweigh the harms.\nPrevalence, risk factors and clinical presentations of post-COVID-19 condition: a follow-up study of reported COVID-19 infections in Montreal, Canada.\nAuthors: Allard, R.; Balegamire, S. J.; Malloum, K. B.; Cantalino, J.; Signor, C.; Leclerc, P.; Bergeron, G.; Mercure, S.-A.; Cadieux, G.\nScore: 149.4, Published: 2023-12-17 DOI: 10.1101/2023.12.15.23300022\nBackground. Meta-analyses suggest that post-COVID-19 condition (PCC) mostly takes three clinical presentations: fatigue, cognitive and respiratory. We sought to estimate the prevalence of these presentations and the strength of their associations with potential risk/protective factors, activity limitations and healthcare utilization. Methods. Follow-up study by telephone re-interview, [\u0026ge;]5 months after initial interview, of a random sample of Montrealers aged 18 years or more, with a PCR-confirmed COVID-19 infection reported between July 18 and December 4, 2021. The re-interview covered age, sex, comorbidities, signs and symptoms (SS), activity limitations, healthcare utilization, perceived stigmatization and psychological distress. Results. Of a sample of 2000 adults, 652 (39.1%) completed the questionnaire. Of 518 with only 1 acute episode of COVID-19, 32.2% met the WHO definition of PCC. Of these, 45.5% reported SS that fit the fatigue presentation, 24.6% the cognitive presentation and 16.8% the respiratory presentation. Neither age nor COVID-19 immunization was associated with PCC, compared to COVID-19 without PCC. However, being female (OR=2.28), hospitalization (OR=2.44) and intensive care (OR=3.21) for the acute COVID-19 episode were. Various activity limitations and types of healthcare utilization were also associated with PCC. All presentations were associated with serious psychological distress. The respiratory presentation was particularly associated with hospitalization for the acute episode (aOR=7.72) and was the only one associated with later hospitalization (aOR=23.6). Interpretation. Our findings suggest that caring for patients with PCC requires adapted organizational models. If they favoured excellence in research, these models could help future studies meet the recommended methodological standards.\nAsymptomatic SARS-CoV-2 infections tend to occur less frequently in developed nations\nAuthors: Chowdhury, S.; Tiwari, A.; James, A.; Chatterjee, B.; Dixit, N. M.\nScore: 29.8, Published: 2023-12-14 DOI: 10.1101/2023.12.14.23299954\nUnlike severe infections, asymptomatic infections occur independently of healthcare access and reflect the natural immunity to SARS-CoV-2. What determines their prevalence,{psi} , and its variation across nations is unknown. We conducted a systematic review of serosurveys performed on samples representative of national populations before vaccination and the emergence of variants. The studies that met our selection criteria together sampled 4,58,489 individuals and yielded estimates of{psi} in 33 nations. Using random-effects modeling, we found the pooled global{psi} to be 45.3% (95% CI: 33.6%-57.5%).{psi} varied widely across nations (range: 6%-96%; I2=99.7%), highlighting the enormous underlying variation in the natural immunity to SARS-CoV-2. Performing meta-regression with national-level metrics, we found that the human development index (HDI) was negatively correlated with{psi} (p=10-13; R2=65.5%). More developed nations thus experienced less frequent asymptomatic infections on average. These findings have implications for unraveling the origins of asymptomatic infections and for future pandemic preparedness.\nAn electronic cigarette pod system delivering 6-methyl nicotine, a synthetic nicotine analog, marketed in the United States as \"PMTA exempt\"\nAuthors: Jordt, S. E.; Jabba, S. V.; Silinski, P.; Berman, M. L.\nScore: 3.2, Published: 2023-11-22 DOI: 10.1101/2023.11.21.23298778\nAs of April 14, 2022, the United States Food and Drug Administration (FDA) has been authorized to regulate tobacco products containing nicotine from any source, including synthetic, requiring manufacturers to submit a premarket tobacco product application (PMTA). A recent report by the World Health Organization (WHO) warned that non-nicotine tobacco alkaloids or other synthetic nicotine analogs could be used by manufacturers to bypass regulatory schemes focusing on nicotine alone. From October 2023 on, vape stores in the United States started selling a new electronic cigarette pod system, named Spree Bar, advertised as \"PMTA exempt\", with youth-appealing flavors and advertising. The products are marketed as containing \"Metatine\", a trademarked name for 6-methyl nicotine, a synthetic nicotine analog patented by a Chinese electronic cigarette manufacturer. Here we used liquid chromatography-mass spectrometry (LCMS) to confirm the presence of a chemical species with the molecular weight of 6-methyl nicotine in Spree Bar e-liquids. The FDA needs to determine whether, in its view, 6-methyl nicotine is a form of \"nicotine\" within the meaning of the Tobacco Control Act, or whether 6-methyl nicotine can be regulated as a drug under the Federal Food, Drug, and Cosmetic Act (FDCA).\n",
  "wordCount" : "1192",
  "inLanguage": "en",
  "datePublished": "2023-12-20T10:36:27Z",
  "dateModified": "2023-12-20T10:36:27Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/public-and-global-health/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      public and global health
    </h1>
    <div class="post-meta">&lt;span&gt;updated on December 20, 2023&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.07.23298573">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.07.23298573" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.07.23298573">
        <p class="paperTitle">Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.07.23298573" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.07.23298573" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Hoffmann, S. S.; Nielsen, S.; Thysen, S. M.; Duriseti, R.; Benn, C. S.</p>
        <p class="info">Score: 1288.5, Published: 2023-12-07 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.07.23298573' target='https://doi.org/10.1101/2023.12.07.23298573'> 10.1101/2023.12.07.23298573</a></p>
        <p class="abstract">ImportancePhase 3 randomized controlled trials (RCTs) of mRNA COVID-19 vaccines in children and adolescents showed efficacy in preventing COVID-19 infections. Vaccines may have non-specific effects; this is not assessed within the current regulatory framework.

ObjectiveConduct a systematic review and meta-analysis of the phase 3 trials to assess overall and non-specific health effects of the mRNA COVID-19 vaccines in children.

Data SourcesPubMed, Embase, Clinical Trials, Web of Science, and regulatory websites were searched for RCTs of mRNA vaccines. The latest trial data was included.

Study SelectionAll RCTs conducted with mRNA vaccines BNT162b2 and mRNA-1237 in children and adolescents below 18 years of age, with placebo, adjuvant, or other vaccines as controls. Two authors independently screened 1199 studies, six were included in the analysis.

Data Extraction and SynthesisData on serious adverse events (SAEs) and severe adverse events (AEs) as well as organ-specific diseases was extracted following the PRISMA reporting guideline, with a focus on non-specific infectious events. Risk Ratios (RRs) comparing vaccine and placebo cohorts were calculated separately for each vaccine and combined in Mantel-Haenszel estimates.

Main Outcomes and MeasuresThe primary outcome was SAEs, overall and infectious. Secondary outcomes were severe AEs and lower respiratory tract infection (LRTI) including RSV.

ResultsThe analyses included 25,549 individuals (17,538 mRNA vaccine recipients and 8,011 placebo recipients). The risk of SAEs was similar for vaccine and placebo recipients. Both mRNA vaccines were associated with increased risk of severe AEs in older children. In a combined analysis, the RR was 3.77 (1.56-9.13[0.4% vs 0.1% in vaccine vs placebo recipients]) in above 5 year-olds, and 0.82 (0.53-1.29)[0.8% vs 0.9%])in younger children (p=0.003 for same effect in older and younger children). In the younger children, mRNA vaccines were associated with higher risk of LRTI (RR=3.03 (1.29-7.09)[0.6% vs 0.2%]).

Conclusions and RelevancemRNA vaccines did not increase the risk of SAEs but were associated with an increased risk of severe AEs in older children, and an increased risk of LRTI in the young. Further research into the overall and non-specific health effects of mRNA vaccines is warranted.

Question, Findings, and MeaningO_ST_ABSQuestionC_ST_ABSWhat is the overall health effect of mRNA COVID-19 vaccines in children?

FindingsIn this systematic review and meta-analysis of phase 3 trials, mRNA vaccine vs. placebo was not associated with increased risk of serious adverse events. The mRNA vaccines were associated with higher risk of severe adverse events in children aged 5 years and older. In children younger than 5 years, mRNA vaccines were associated with a 3-fold higher risk of lower respiratory tract infections.

MeaningThe results suggest that mRNA vaccines are associated with increased risk of severe adverse events and increased risk of LRTI. Given the low risk of severe COVID-19 infection in children, it is not clear that the benefits of COVID-19 vaccines in children outweigh the harms.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.15.23300022">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.15.23300022" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.15.23300022">
        <p class="paperTitle">Prevalence, risk factors and clinical presentations of post-COVID-19 condition: a follow-up study of reported COVID-19 infections in Montreal, Canada.</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.15.23300022" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.15.23300022" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Allard, R.; Balegamire, S. J.; Malloum, K. B.; Cantalino, J.; Signor, C.; Leclerc, P.; Bergeron, G.; Mercure, S.-A.; Cadieux, G.</p>
        <p class="info">Score: 149.4, Published: 2023-12-17 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.15.23300022' target='https://doi.org/10.1101/2023.12.15.23300022'> 10.1101/2023.12.15.23300022</a></p>
        <p class="abstract">Background. Meta-analyses suggest that post-COVID-19 condition (PCC) mostly takes three clinical presentations: fatigue, cognitive and respiratory. We sought to estimate the prevalence of these presentations and the strength of their associations with potential risk/protective factors, activity limitations and healthcare utilization. Methods. Follow-up study by telephone re-interview, [&amp;ge;]5 months after initial interview, of a random sample of Montrealers aged 18 years or more, with a PCR-confirmed COVID-19 infection reported between July 18 and December 4, 2021. The re-interview covered age, sex, comorbidities, signs and symptoms (SS), activity limitations, healthcare utilization, perceived stigmatization and psychological distress. Results. Of a sample of 2000 adults, 652 (39.1%) completed the questionnaire. Of 518 with only 1 acute episode of COVID-19, 32.2% met the WHO definition of PCC. Of these, 45.5% reported SS that fit the fatigue presentation, 24.6% the cognitive presentation and 16.8% the respiratory presentation. Neither age nor COVID-19 immunization was associated with PCC, compared to COVID-19 without PCC. However, being female (OR=2.28), hospitalization (OR=2.44) and intensive care (OR=3.21) for the acute COVID-19 episode were. Various activity limitations and types of healthcare utilization were also associated with PCC. All presentations were associated with serious psychological distress. The respiratory presentation was particularly associated with hospitalization for the acute episode (aOR=7.72) and was the only one associated with later hospitalization (aOR=23.6). Interpretation. Our findings suggest that caring for patients with PCC requires adapted organizational models. If they favoured excellence in research, these models could help future studies meet the recommended methodological standards.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.14.23299954">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.14.23299954" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.14.23299954">
        <p class="paperTitle">Asymptomatic SARS-CoV-2 infections tend to occur less frequently in developed nations</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.14.23299954" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.14.23299954" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Chowdhury, S.; Tiwari, A.; James, A.; Chatterjee, B.; Dixit, N. M.</p>
        <p class="info">Score: 29.8, Published: 2023-12-14 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.14.23299954' target='https://doi.org/10.1101/2023.12.14.23299954'> 10.1101/2023.12.14.23299954</a></p>
        <p class="abstract">Unlike severe infections, asymptomatic infections occur independently of healthcare access and reflect the natural immunity to SARS-CoV-2. What determines their prevalence,{psi} , and its variation across nations is unknown. We conducted a systematic review of serosurveys performed on samples representative of national populations before vaccination and the emergence of variants. The studies that met our selection criteria together sampled 4,58,489 individuals and yielded estimates of{psi} in 33 nations. Using random-effects modeling, we found the pooled global{psi} to be 45.3% (95% CI: 33.6%-57.5%).{psi} varied widely across nations (range: 6%-96%; I2=99.7%), highlighting the enormous underlying variation in the natural immunity to SARS-CoV-2. Performing meta-regression with national-level metrics, we found that the human development index (HDI) was negatively correlated with{psi} (p=10-13; R2=65.5%). More developed nations thus experienced less frequent asymptomatic infections on average. These findings have implications for unraveling the origins of asymptomatic infections and for future pandemic preparedness.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.11.21.23298778">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.11.21.23298778" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.11.21.23298778">
        <p class="paperTitle">An electronic cigarette pod system delivering 6-methyl nicotine, a synthetic nicotine analog, marketed in the United States as &#34;PMTA exempt&#34;</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.11.21.23298778" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.11.21.23298778" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Jordt, S. E.; Jabba, S. V.; Silinski, P.; Berman, M. L.</p>
        <p class="info">Score: 3.2, Published: 2023-11-22 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.11.21.23298778' target='https://doi.org/10.1101/2023.11.21.23298778'> 10.1101/2023.11.21.23298778</a></p>
        <p class="abstract">As of April 14, 2022, the United States Food and Drug Administration (FDA) has been authorized to regulate tobacco products containing nicotine from any source, including synthetic, requiring manufacturers to submit a premarket tobacco product application (PMTA). A recent report by the World Health Organization (WHO) warned that non-nicotine tobacco alkaloids or other synthetic nicotine analogs could be used by manufacturers to bypass regulatory schemes focusing on nicotine alone. From October 2023 on, vape stores in the United States started selling a new electronic cigarette pod system, named Spree Bar, advertised as &#34;PMTA exempt&#34;, with youth-appealing flavors and advertising. The products are marketed as containing &#34;Metatine&#34;, a trademarked name for 6-methyl nicotine, a synthetic nicotine analog patented by a Chinese electronic cigarette manufacturer. Here we used liquid chromatography-mass spectrometry (LCMS) to confirm the presence of a chemical species with the molecular weight of 6-methyl nicotine in Spree Bar e-liquids. The FDA needs to determine whether, in its view, 6-methyl nicotine is a form of &#34;nicotine&#34; within the meaning of the Tobacco Control Act, or whether 6-methyl nicotine can be regulated as a drug under the Federal Food, Drug, and Cosmetic Act (FDCA).</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
